Design, synthesis, and characterization of dipeptide isostere containing cis-epoxide for the irreversible inactivation of HIV protease

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 6, 1996, Pages 589-594

  Lee, Chang Sun ^a   Choy, Nakyen ^a   Park, Chihyo ^a   Choi, Hoil ^a   Son, Young Chan ^a   Kim, Sangsoo ^a   Ok, Jong Hoa ^a   Yoon, Heungsik ^a   Kim, Sung Chun ^a  

^a LG Chemical Ltd   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; EPOXIDE; PROTEINASE INHIBITOR; PSEUDOPEPTIDE;

ARTICLE; COMPUTER SIMULATION; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

EID: 0029872085     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-894X(96)00087-X     Document Type: Article

References (21)

1. (a) Roberts, N. A.; Martin, J. A.; Kinchington, D.; Broadhurst, A. U.; Craig, J. C.; Duncan, I. B.; Galpin, S. A.; Handa, B. K.; Kay, J.; Krohn, A.; Lambert, R. W.; Merrett, J. H.; Mills, J. S.; Parkes, K. E. B.; Redshaw, S.; Ritchie, A. J.; Taylor, D. L.; Thomas, G. J.; Machin, P. J. Science 1990, 248, 358.;
2. (b) Kempf, D. J.; Norbeck, D. W.; Codacovi, L. M.; Wang, X. C.; Kohlbrenner, W. E.; Wideburg, N. E.; Paul, D. A.; Knigge, M. F.; Vasavanonda, S.; Craig-Kennard, A.; Saldivar, A.; Rossenbrook, Jr., W.; Clement, J. J.; Plattner, J. J.; Erickson, J. J. Med Chem. 1990, 33 2687.
3. Walsh, C. Tetrahedron 1982, 38 871.
4. Furfine, E. S.; D'Souza, E.; Ingold, K. J.; Leban, J. J.; Spector, T.; Porter, D. J. Biochemistry 1992, 31 7886.
5. (a) Davies, D. R. Annu. Rev. Biophys.BioPhys.Chem. 1990, 19 189;
6. (b) Rich, D. H. J. Med Chem. 1985, 28 263.
7. (a) Hyland, L. J.; Tomaszek, Jr., T. A.; Roberts, G. D.; Carr, S. A.; Magaard, V. W.; Bryan, H. L.; Fakhoury, S. A.; Moore, M. L.; Minnich, M. D.; Culp, J. S.; DesJarlais, R. L.; Meek, T. D. Biochemistry 1991, 30 8441.;
8. (b) Hyland, L. J.; Tomaszek, Jr., T. A; Meek, T. D. Biochemistry 1991, 30 8454.
9. Meek, T. D.; Dayton, B. D.; Metcalf, B. W.; Dreyer, G. B.; Strickler, J. E.; Gorniak, J. G.; Rosenberg, M.; Moore, M. L.; Magaard, V. W.; Debouck, C. Proc. Natl. Acad Sci. U. S. A. 1989, 86 1841.
10. Moelling, K.; Schulze, T.; Knoop, M-T.; Kay, J.; Jupp, R.; Nicolaou, G.; Pearl, L. H. FEBS Lett. 1990, 261 373.;
11. (b) Pal, R.; Gallo, R. C.; Sarngadharan, M. G. Proc. Natl. Acad. Sci. U. S. A. 1988, 85 9283.
12. Grant, S. K.; Moore, M. L.; Fakhoury, S. A.; Tomaszek, Jr., T. A.; Meek, T. D. Bioorg. Med. Chem. Lett. 1992, 2 1441.
13. (a) Erickson, J.; Neidhart, D. J.; VanDrie, J.; Kempf, D. J.; Wang, X. C.; Norbeck, D. W.; Plattner, J. J.; Rittenhouse, J. W.; Turon, M.; Wideburg, N.; Kohlbrenner, W. E.; Simmer, R.; Helfrich, R.; Paul, D. A.; Knigge, M. Science 1990, 249 527.;
14. (b) Miller, M.; Schneider, J.; Sathyanarayana, B. K.; Toth, M. V.; Marshall, G. R.; Clawson, L.; Selk, L.; Kent, S. B. H.; Wlodawer, A.; Science 1990, 246 1149.
15. Solid state deuterium nuclear magnetic resonance experiments on the compound V showed a pake pattern with full width and long T1, which were major characteristics of slow motion of molecules. Therefore, the local motion of the compound 10 is slow and its structure is rigid. Formula presented.
16. (a) Corey, E. J.; Raju, N. Tetrahedron Lett. 1983, 24 5571;
17. (b) Keinan, E.; Sinha, S. C.; Singh, S. P. Tetrahedron 1991, 47 4631.
18. Johnson, R. L. J. Med. Chem. 1984, 27 1351.
19. Ludy, J. R.; Dellaria, J. F.; Plattner, J. J.; Soderquist, J.; Yi, N. J. Org. Chem. 1987, 52 1487.
20. Park, C.; Koh, J. S.; Son, Y. C.; Choi, H.; Lee, C. S.; Choy, N.; Moon, K. Y.; Jung, W. H.; Kim, S. C.; Yoon, H. Bioorg. Med. Chem. Lett 1995, 5 1843.
21. 2)-Phe-Phe-Val-Leu-4-(hydroxymethyl)pyridine ester (BACHEM Chemical Co.) by human cathepsin D was followed at pH 3.4 using HPLC according to the method of Marossy, K.; Rich, D. H. Anal. Biochem. 1983, 130 158. At pH 3.4, compound 9 was stable after 3 days' incubation under the used buffer condition.